Provided the KCNQ1/TRPM4 dual mutation patient was not responding well to conventional medications and suffered relapses of LQTS symptoms, verapamil (oral, 40 mg, 3 times per day) was added to the treatment regime. The gene discussed is KCNQ1; the disease is familial long QT syndrome.